LivePerson, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by LivePerson, Inc. on October 20, 2025, covering events occurring on October 14, 2025. The filing primarily addresses corporate governance changes resulting from a previously announced debt restructuring agreement.
Key Financial Metrics
The filing does not report standard operating financial metrics such as revenue, profit, cash flow, or margins. However, it discloses specific financial consideration details related to a debt exchange transaction involving Palogic Value Fund, LP:
- Cash Consideration: Approximately $1.3 million.
- Debt Issuance: Approximately $3.3 million principal amount of Second Lien Senior Subordinated Secured Notes due 2029.
- Equity Issuance: 1,592,984 shares of common stock (106,198 shares on a post-reverse-split basis) and 762 shares of Series B Fixed Rate Convertible Perpetual Preferred Stock.
Material Changes
The primary material change is the appointment of Ryan L. Vardeman as a Class III director to the Board of Directors, effective October 14, 2025. His term expires at the 2027 Annual Meeting of Stockholders. This appointment was made pursuant to the Exchange Agreement dated August 11, 2025, between the Company and holders of its 0% Senior Convertible Notes due 2026.
Outlook, Risks, and Management Commentary
Management commentary is limited to the background of the new director and the terms of his appointment. Mr. Vardeman brings extensive experience in corporate strategy, capital structure analysis, and technology investing. He will receive standard annual director fees and an initial equity grant under the Company's 2019 Stock Incentive Plan. The filing notes that the Company intends to enter into a standard director indemnification agreement with Mr. Vardeman. No specific forward-looking guidance or new risk factors were disclosed in this report.
Key Facts for Investor Verification
- Verify the terms of the August 11, 2025 Exchange Agreement to understand the full scope of the debt restructuring.
- Confirm the impact of the 1,592,984 shares issued to Palogic Value Fund, LP on total outstanding share count and dilution.
- Review the specific terms of the new Second Lien Senior Subordinated Secured Notes due 2029.
- Monitor future disclosures regarding Mr. Vardeman's committee appointments on the Board.